|
Mr. Broshy is the Chairman and Chief Executive Officer of inVentiv Health, Inc. (Nasdaq: VTIV). inVentiv Health is the leading provider of commercialization and complementary services to the global pharmaceutical, life sciences and biotechnology industries, supporting the needs of over 200 unique clients including all top 20 global pharmaceutical companies. inVentiv delivers a broad range of customized clinical, sales, marketing and communications solutions through its three core business segments: inVentiv Clinical, inVentiv Communications and inVentiv Commercial. Mr. Broshy joined inVentiv Health as Chief Executive Officer and Director in June 1999, took the company public in the fall of 1999, and additionally became Chairman of the Board in June 2006.
Mr. Broshy has over 21 years' management and consulting experience within the healthcare industry and is a widely recognized industry expert and frequent speaker on strategic issues in the pharmaceutical and healthcare industries. Prior to joining inVentiv he served as the Partner responsible for the healthcare practice of The Boston Consulting Group (BCG) across the Americas. During his fourteen-year tenure at BCG from 1984 to 1998, Mr. Broshy consulted widely with senior executives from a number of the major global pharmaceutical manufacturers, managed care organizations, and academic medical centers, and advised on a range of strategic, organizational and operational issues. Mr. Broshy has also served as President and Chief Executive Officer of Coelacanth Corporation, a privately-held biotechnology company.
Mr. Broshy currently also serves as a Director of Neurogen Corporation (Nasdaq: NRGN), a biotechnology company, and on the Simon Wiesenthal Center’s NY Executive Board. Mr. Broshy is a graduate of Harvard University (M.B.A.), Stanford University (M.S.), and Massachusetts Institute of Technology (B.S.). | 